July MIMS update

Some of the recent changes to the medicines landscape, with new products, indications and contraindications  New Products Canakinumab (rmc) (Ilaris) is a human monoclonal anti-human interleukin (IL)-1beta antibody of the IgG1/kappa isotype. Excess production of IL-1beta in inflammatory diseases leads to local or systemic inflammation, increased production of the inflammatory markers C-reactive protein or serum